Esperion Therapeutics ESPR Ratios & Valuation
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Operating margin | 18.1%+3.2pp | 15%+23.2pp | -8.2%+3.4pp | -11.6%+2.1pp | -13.7%-31.4pp | |
| EBITDA margin | 18.1%+3.2pp | 15%+23.2pp | -8.2%+3.4pp | -11.5%+2.1pp | -13.7%-31.4pp | |
| Efficiency | ||||||
| Asset turnover | 1.1×+0.1× | 1×+0.1× | 0.9×+0.1× | 0.8×0.0× | 0.7×-0.5× | |
| Liquidity | ||||||
| Current ratio | 1.5×0.0× | 1.5×+0.5× | 1×-0.1× | 1.1×0.0× | 1.2×-0.2× | |
| Quick ratio | 1.2×0.0× | 1.2×+0.5× | 0.7×-0.1× | 0.8×0.0× | 0.8×-0.2× | |
| Cash ratio | 0.5×0.0× | 0.6×+0.3× | 0.3×0.0× | 0.3×-0.1× | 0.4×-0.2× | |
| Leverage | ||||||
| Debt-to-assets | 0.3×0.0× | 0.3×-0.1× | 0.4×0.0× | 0.4×0.0× | 0.5×0.0× | |
| Net debt / EBITDA | -0×+0.2× | -0.2×— | —— | —— | —— | |
| Interest coverage | 0.9×+0.2× | 0.7×+1.0× | -0.3×+0.1× | -0.4×+0.1× | -0.5×-1.5× | |
| Per Share | ||||||
| Book value per share | -$1.23+15.7% | -$1.45+35.4% | -$2.25-2.5% | -$2.19-1.0% | -$2.17-4.6% | |
| Valuation | ||||||
| Market capitalization | $811.73M+283% | $877.16M+64.2% | $534.3M+152% | $212.07M-25.6% | $284.9M-34.3% | |
| Enterprise value | $810.81M+233% | $864.28M+44.9% | $596.66M+116% | $276.51M-12.6% | $316.51M-27.2% | |
| Price / sales | 1.9×+1.1× | 2.2×+0.4× | 1.8×+1.0× | 0.8×-0.3× | 1.1×-0.2× | |
| EV / EBITDA | 10.7×— | 14.3×— | —— | —— | —— | |
| EV / sales | 1.9×+1.0× | 2.1×+0.2× | 2×+0.9× | 1×-0.2× | 1.2×-0.1× |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where do Esperion Therapeutics's ratios come from?
- Every ratio is computed from Esperion Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
